Clinical value analysis of ulinastatin in autoimmune liver disease with chronic plus acute liver failure
乌司他丁治疗自身免疫性肝病合并慢加急性肝衰竭的临床价值分析

摘要

目的 分析自身免疫性肝病合并慢加急性肝衰竭患者治疗中添加乌司他丁的临床价值。方法 本次病例筛选在我院接受治疗的自身免疫性肝病合并慢加急性肝衰竭患者120例，将入选的病例采取随机数字表法分成两组，组别类型为观察组和对照组，每组患者各有60例，对照组患者给予常规治疗，观察组则添加乌司他丁治疗，详细分析对比两组最终获得的治疗效果。结果 两组结果比较显示，观察组患者症状改善时间短于对照组，患者的肝功能改善效果优于对照组，取得的治疗总有效率明显高于对照组，（P＜0.05）。结论 对自身免疫性肝病伴慢加急性肝衰竭患者治疗中添加乌司他丁，可使临床治疗效果得到进一步提升，减轻患者肝功能损伤程度，降低疾病的危害性。

Abstract

Objective To analyze the clinical value of ulinastatin in the treatment of patients with autoimmune liver disease complicated with chronic and acute liver failure.
Methods A total of 120 patients with autoimmune liver disease complicated with chronic and acute liver failure received treatment in our hospital were selected and divided into two groups by random number table method: observation group and control group, with 60 patients in each group. The control group received conventional treatment, while the observation group was treated with ulinastatin. The final therapeutic effect of the two groups was analyzed and compared in detail.
Results The results of the two groups showed that the improvement time of symptoms in the observation group was shorter than that in the control group, the improvement effect of liver function in the patients was better than that in the control group, and the total effective rate was significantly higher than that in the control group (P < 0.05).
Conclusion   Adding ulinastatin to the treatment of patients with autoimmune liver disease combined with chronic and acute liver failure can further improve the clinical therapeutic effect, reduce the degree of liver function injury and reduce the harm of the disease.